<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03833440</url>
  </required_header>
  <id_info>
    <org_study_id>2018-21</org_study_id>
    <secondary_id>2018-000914-39</secondary_id>
    <nct_id>NCT03833440</nct_id>
  </id_info>
  <brief_title>Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance</brief_title>
  <acronym>PIONeeR</acronym>
  <official_title>Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR Clinical Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research Hypothesis Lung cancer is the leading cause of cancer-related mortality in France&#xD;
      and in western countries, accounting for more than 1.8 million new cases and 1.5 million&#xD;
      deaths worldwide in 2012. Recent advances in the management of patients with Non-small Cell&#xD;
      Lung Cancer Patients (NSCLC) include the use of therapies targeting oncogenes but a molecular&#xD;
      alteration is currently found in only the half of the non-squamous NSCLC . More recently,&#xD;
      immune check point inhibitors (ICI), firstly targeting PD-(L)1, became available and&#xD;
      demonstrate an overall survival advantage over standard second-line chemotherapy both in&#xD;
      squamous and non-squamous NSCLC. Unfortunately, this global overall survival benefit is&#xD;
      driven by approximately 20% of the patient's population while a large majority of patients is&#xD;
      in fact progressing in the first weeks of treatment.&#xD;
&#xD;
      In the context of personalized medicine, innovative immunotherapy strategies in oncology are&#xD;
      based on the principle of immune-contexture and require:&#xD;
&#xD;
        -  The identification of biomarkers for assessing the specific immune-contexture of each&#xD;
           patient (microenvironment, tumors and effector cells)&#xD;
&#xD;
        -  The development of new treatments targeting their appropriate effector cells in&#xD;
           monotherapy or combination treatments.&#xD;
&#xD;
      The current PIONEER-Clinical study is aimed at assessing how to overcome resistance to ICIs&#xD;
      monotherapies or ICI in combination with platinum-based chemotherapies, with experimental&#xD;
      precision immunotherapies combined to Durvalumab in 2nd, 3rd or 4th line, in advanced NSCLC&#xD;
      progressors patients after up to 18more than 6 w. of anti PD (L) 1. for ICIs monotherapies&#xD;
      and after more than 12w. of anti PD(L)1 in combination with chemotherapies.&#xD;
&#xD;
      Some supplementary blood and tissue samples are aimed at identification of personalized&#xD;
      patients' biomarkers, correlation of them with the efficacy endpoints, in order to better&#xD;
      understand mechanisms of resistance and improve their future treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:&#xD;
&#xD;
      During a mandatory post treatment 28-day wash-out period, 135 advanced NSCLC patients with&#xD;
      progressive disease evaluated between 6 and 18w. of a second or third line ICI monotherapy;&#xD;
      will undergo a screening visit. After signing an informed written consent, if they are found&#xD;
      eligible, their participation in the study will ensue.&#xD;
&#xD;
      Treatment allocation will be performed using the randomization module of the eCRF, :&#xD;
&#xD;
        -  Arm A: combination of Durvalumab (MEDI4736) + Monalizumab (IPH2201), to target a PD-L1&#xD;
           co-inhibitory pathway&#xD;
&#xD;
        -  Arm B: combination of Durvalumab + oleclumab (MEDI9447), to target limitations of&#xD;
           antitumor T-cell immunity caused by adenosine receptor signaling (inclusions closed on&#xD;
           May 10, 2021)&#xD;
&#xD;
        -  Arm C: combination of Durvalumab + AZD6738, to potentially enhance anti- tumour T-cell&#xD;
           responses&#xD;
&#xD;
        -  Arm D: a standard third or forth-line chemotherapy maintenance (Docetaxel)&#xD;
&#xD;
        -  Arm E : combination of Durvalumab + MET kinase inhibitor Savolitinib (AZD6094)&#xD;
&#xD;
      A maximum of 120 patients will be randomized, with 30 patients per arm (4 arms).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm A: combination of Durvalumab + NKG2A inhibitor Monalizumab (IPH2201), to target a PD-L1 co-inhibitory pathway&#xD;
Arm B: combination of Durvalumab + CD73 antibody MEDI9447, to target limitations of antitumor T-cell immunity caused by adenosine receptor signaling&#xD;
Arm C: combination of Durvalumab + ATR inhibitor AZD6738, to potentially enhance anti- tumour T-cell responses&#xD;
Arm D: a standard third or forth-line chemotherapy maintenance (Docetaxel).&#xD;
Arm E : combination of Durvalumab + MET kinase inhibitor Savolitinib (AZD6094)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the 12-week Disease Control Rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>in each arm of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>12 months</time_frame>
    <description>the proportion of patients with complete response (CR) or partial response (PR) as best overall response over the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS Ratio</measure>
    <time_frame>12 months</time_frame>
    <description>the date of randomization until the date of event defined as the first documented progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>measured from the date of randomization to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>4years</time_frame>
    <description>measured in to patients whose Best overall response is either CR or PR. It will be measured from the time of first documented response (CR or PR) until the first documented disease progression or death due to underlying cancer.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Durvalumab + Monalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab + MEDI9447</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab + AZD6738</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>durvalumab+savolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab (MEDI4736)</intervention_name>
    <description>1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days&#xD;
EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days&#xD;
c=cycle D= day</description>
    <arm_group_label>Durvalumab + AZD6738</arm_group_label>
    <arm_group_label>Durvalumab + MEDI9447</arm_group_label>
    <arm_group_label>Durvalumab + Monalizumab</arm_group_label>
    <arm_group_label>durvalumab+savolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monalizumab (IPH2201)</intervention_name>
    <description>1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days&#xD;
c=cycle D= day</description>
    <arm_group_label>Durvalumab + Monalizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oleclumab (MEDI9447)</intervention_name>
    <description>3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.&#xD;
c=cycle D= day</description>
    <arm_group_label>Durvalumab + MEDI9447</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceralasertib (AZD6738)</intervention_name>
    <description>240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.&#xD;
CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days&#xD;
c=cycle D= day</description>
    <arm_group_label>Durvalumab + AZD6738</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOCETAXEL</intervention_name>
    <description>75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days&#xD;
c=cycle D= day</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Savolitinib</intervention_name>
    <description>600 mg QD&#xD;
1 cycle = 28 days</description>
    <arm_group_label>durvalumab+savolitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to give a signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in this&#xD;
             protocol. Written informed consent obtained from the patient prior to performing any&#xD;
             protocol-related procedures, including screening evaluations.&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Patients must have histologically confirmed diagnosis of advanced (proven advanced&#xD;
             stage) or recurrent NSCLC, (both squamous and non-squamous pathologies are accepted;&#xD;
             patients with a mixed NSCLC and SCLC component are ineligible)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Body weight &gt;35kg&#xD;
&#xD;
          -  Patients with evidence of radiological progression after more than 6 weeks of a&#xD;
             registered second or third line PD1 or PD-L1 inhibitor in monotherapy (to include ,&#xD;
             Nivolumab, Pembrolizumab, Atezolizumab) or more than 12 weeks for a first line PD-1 or&#xD;
             PD-L1 inhibitor in combination with platinum-based chemotherapy.Patients who have&#xD;
             received immunotherapy in the maintenance setting can only have had one prior regimen&#xD;
             containing PD-1/L1 inhibitor. No intervening treatment between the immunotherapy and&#xD;
             entry into this study is permitted.&#xD;
&#xD;
          -  Patients with known actionable molecular alteration (EGFR activating mutation, ALK&#xD;
             rearrangement, ROS1 rearrangement) should have received a commercially available&#xD;
             specific inhibitor&#xD;
&#xD;
          -  Patients must have an available archived tissue from a standard tumor biopsy for PD-L1&#xD;
             assessment, done before PD-1 ICI initiation.&#xD;
&#xD;
          -  As of Week 1 Day 1, subjects with central nervous system (CNS) metastases must have&#xD;
             been treated and must be asymptomatic and meet the following:&#xD;
&#xD;
               1. No concurrent treatment, inclusive of but not limited to surgery, radiation,&#xD;
                  and/or corticosteroids&#xD;
&#xD;
               2. At least 14 days after CNS treatment, clinically stable with no symptoms of CNS&#xD;
                  metastasis or sequelae of radiation and at least 14 days since last dose of&#xD;
                  corticosteroids NOTE: Subjects with clinical symptoms or cord compression or with&#xD;
                  leptomeningeal disease are excluded from the study&#xD;
&#xD;
          -  Adequate organ and bone marrow function as defined below:&#xD;
&#xD;
               1. Haemoglobin ≥10.0 g/dL (transfusion to achieve this level is not permitted within&#xD;
                  2 weeks of first study drug administration)&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) 1.5 x (&gt; 1500 per mm3) (stable off any growth&#xD;
                  factor within 4 weeks of first study drug administration)&#xD;
&#xD;
               3. Platelet count ≥100 x 109/L (&gt;100,000 per mm3) (transfusion to achieve this level&#xD;
                  is not permitted within 2 weeks of first study drug administration)&#xD;
&#xD;
               4. Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). This will not&#xD;
                  apply to patients with confirmed Gilbert's syndrome (no upper limit for those&#xD;
                  patients with persistent or recurrent hyperbilirubinemia that is predominantly&#xD;
                  unconjugated in the absence of hemolysis or hepatic pathology, ≤3 x ULN for&#xD;
                  patients with liver metastases), who will be allowed only in consultation with&#xD;
                  their physician.&#xD;
&#xD;
               5. Normal thyroid function, subclinical hypothyroidism (TSH &lt; 10 mIU/mL) or have&#xD;
                  controlled thyroid disorder&#xD;
&#xD;
               6. AST (SGOT)/ALT (SGPT) ≤2.5 x institutional upper limit of normal unless liver&#xD;
                  metastases are present, in which case it must be ≤5x ULN&#xD;
&#xD;
               7. Measured creatinine clearance (CL) &gt;45 mL/min or Calculated creatinine CL&gt;45&#xD;
                  mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour&#xD;
                  urine collection for determination of creatinine clearance.&#xD;
&#xD;
          -  Women must not be breastfeeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals deprived of liberty or placed under the authority of a tutor&#xD;
&#xD;
          -  Patient unable to understand, read and/or sign an informed consent&#xD;
&#xD;
          -  Absence of a measurable target lesion according to RECIST criteria 1.1&#xD;
&#xD;
          -  Any symptomatic or untreated brain metastasis&#xD;
&#xD;
          -  Any previous treatment with Docetaxel&#xD;
&#xD;
          -  Prior randomisation or treatment with durvalumab AZD6738, Medi9447, Monalizumab&#xD;
&#xD;
          -  Concurrent enrolment in another clinical study, unless it is an observational&#xD;
             (non-interventional) clinical study or during the follow-up period of an&#xD;
             interventional study&#xD;
&#xD;
          -  Any previous treatment with a PD1 or PD-L1 inhibitor with the following events:&#xD;
&#xD;
               1. Must not have experienced a toxicity that led to permanent discontinuation of&#xD;
                  prior immunotherapy.&#xD;
&#xD;
               2. All AEs while receiving prior immunotherapy must have completely resolved or&#xD;
                  resolved to baseline prior to screening for this study.&#xD;
&#xD;
               3. Must not have experienced a ≥Grade 3 immune related AE or an immune related&#xD;
                  neurologic or ocular AE of any grade while receiving prior immunotherapy.&#xD;
&#xD;
               4. Must not have required the use of additional immunosuppression other than&#xD;
                  corticosteroids for the management of an AE, not have experienced recurrence of&#xD;
                  an AE if re-challenged, and not currently require maintenance doses of &gt; 10 mg&#xD;
                  prednisone or equivalent per day&#xD;
&#xD;
               5. No systemic intervening treatment between progression on ICI and entry into this&#xD;
                  study&#xD;
&#xD;
          -  Last dose of immunotherapy ≤21 days prior to the first dose of study drug.&#xD;
&#xD;
          -  The patient can receive a stable dose of bisphosphonates or denosumab for bone&#xD;
             metastases, before and during the study as long as these were started at least 5 days&#xD;
             prior to the study treatment.&#xD;
&#xD;
          -  Current or prior use of steroids or other immunosuppressive medication within 28 days&#xD;
             before the first dose of durvalumab, with the exceptions of intranasal and inhaled&#xD;
             corticosteroids or systemic corticosteroids at physiological doses, which do not&#xD;
             exceed 10 mg/day of prednisone, or an equivalent corticosteroid. - Any unresolved&#xD;
             toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of&#xD;
             alopecia, vitiligo, and the laboratory values defined in the inclusion criteria&#xD;
&#xD;
          -  Palliative radiotherapy (to a non target lesion) must have been completed at least 7&#xD;
             days before Cycle 1 Day 1 (with the exception of patients receiving radiation to more&#xD;
             than 30% of the bone marrow or with a wide field of radiation who must have completed&#xD;
             treatment within 28 days of the first dose of study treatment).&#xD;
&#xD;
          -  Major surgical procedure (as defined by the Investigator) within 28 days prior to the&#xD;
             first dose of IMP : patients must have recovered from any effects of any major surgery&#xD;
             Note: Localsurgery and other procedures (radiotherapy) of isolated lesions for&#xD;
             palliative intent is acceptable.&#xD;
&#xD;
          -  History of allogenic organ or stem cell transplantation.&#xD;
&#xD;
          -  Active or prior documented autoimmune related inflammatory disorders treated with&#xD;
             systemic immunosuppressive drugs within the last 3 months or history of clinically&#xD;
             severe auto-immune disease (including inflammatory bowel disease [e.g., colitis or&#xD;
             Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic&#xD;
             lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with&#xD;
             polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]).&#xD;
&#xD;
          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic&#xD;
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirement, substantially increase&#xD;
             risk of incurring AEs or compromise the ability of the patient to give written&#xD;
             informed consent&#xD;
&#xD;
          -  Any other malignancy which has been active or treated within the past three years,with&#xD;
             the exception of :&#xD;
&#xD;
               1. cervical intra-epithelial neoplasia,&#xD;
&#xD;
               2. non-melanoma skin cancer, or lentigo maligna without evidence of disease&#xD;
&#xD;
               3. ductal Carcinoma in Situ (DCIS),&#xD;
&#xD;
               4. stage 1 grade 1 endometrial carcinoma,&#xD;
&#xD;
               5. or other solid tumours curatively treated with no evidence of disease for ≥ 5&#xD;
                  years prior to study entry&#xD;
&#xD;
          -  History of leptomeningeal carcinomatosis&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms&#xD;
             calculated from 3 ECGs (within 15 minutes at 5 minutes apart) For durvalumab in&#xD;
             combination with an agent with pro-arrhythmic potential or where effect of the&#xD;
             combination on QT is not known if this criterion should be retained. Patient safety&#xD;
             and the cardiac EKG should be consulted as needed.&#xD;
&#xD;
          -  History of active primary immunodeficiency&#xD;
&#xD;
          -  Active infection including tuberculosis (clinical evaluation that includes clinical&#xD;
             history, physical examination and radiographic findings, and TB testing in line with&#xD;
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),&#xD;
             hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients&#xD;
             with a past or resolved HBV infection (defined as the presence of hepatitis B core&#xD;
             antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for&#xD;
             hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative&#xD;
             for HCV RNA.&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of&#xD;
             Investigational Medicinal Product (IMP).&#xD;
&#xD;
        Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to&#xD;
        30 days after the last dose of IP.&#xD;
&#xD;
          -  Female patients who are pregnant or breastfeeding or male or female patients of&#xD;
             reproductive potential who are not willing to employ effective birth control from&#xD;
             screening to 180 days after the last dose of durvalumab in combination with an other&#xD;
             agent.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any of the study drugs or any of the study drug&#xD;
             excipients.&#xD;
&#xD;
          -  Judgment by the investigator that the patient is unsuitable to participate in the&#xD;
             study and the patient is unlikely to comply with study procedures, restrictions and&#xD;
             requirements.&#xD;
&#xD;
          -  A diagnosis of ataxia telangiectasia&#xD;
&#xD;
          -  Refractory nausea and vomiting, chronic gastrointestinal diseases or previous&#xD;
             significant bowel resection, with clinically significant sequelae&#xD;
&#xD;
          -  Patients receiving, or having received, concomitant medications, herbal supplements&#xD;
             and/or foods that significantly modulate cytochrome P450 3A4 (CYP3A4) or&#xD;
             P-glycoprotein (P-gp) activity (washout periods of 5 half-lives( minimum2 weeks), but&#xD;
             3 weeks for St. John's Wort). NOTE these include common azole antifungals, macrolide&#xD;
             antibiotics and other medications.&#xD;
&#xD;
          -  Patient has had prescription or non-prescription drugs or other products known to be&#xD;
             CYP3A4 and/or CYP2B6 substrates or CYP3A4 and/or CYP2B6 substrates with a narrow&#xD;
             therapeutic index. Exposure of other drugs metabolised by CYP3A4 and/or CYP2B6 may be&#xD;
             reduced and additional monitoring may be required, see Appendix E.&#xD;
&#xD;
          -  The use of herbal supplements or 'folk remedies' (and medications and foods that&#xD;
             significantly modulate CYP3A activity) should be discouraged. If deemed necessary,&#xD;
             such products may be administered with caution and the reason for use documented in&#xD;
             the CRF. Please see Appendix E, for further details.&#xD;
&#xD;
          -  Patients with relative hypotension (&lt;90/60 mmHg) or clinically relevant orthostatic&#xD;
             hypotension, including a fall in blood pressure of &gt;20 mmHg at screening.&#xD;
&#xD;
          -  Any of the following cardiac criteria currently or within the last 6 months (by New&#xD;
             York Heart Association (NYHA) ≥ Class 2 where applicable)&#xD;
&#xD;
               1. Patients at risk of brain perfusion problems, e.g., medical history of carotid&#xD;
                  stenosis or pre-syncopal or syncopal episodes, history of TIAs&#xD;
&#xD;
               2. Uncontrolled hypertension (grade 2 or above) requiring clinical intervention&#xD;
&#xD;
               3. Mean resting corrected QT interval (QTc) &gt;470 msec for females and &gt;450 for&#xD;
                  men,obtained from 3 electrocardiograms (ECGs) 5-10 minutes apart using the&#xD;
                  Fredericia formula&#xD;
&#xD;
               4. Conduction abnormality not controlled with pacemaker or medication e.g. complete&#xD;
                  left bundle branch block, third degree heart block&#xD;
&#xD;
               5. Any factors that increase the risk of QTc prolongation or risk of arrhythmic&#xD;
                  events such as hypokalaemia, congenital long QT syndrome, immediate family&#xD;
                  history of long QT syndrome or unexplained sudden death under 40 years of age&#xD;
&#xD;
               6. Unstable angina pectoris or acute myocardial infarction&#xD;
&#xD;
               7. Congestive heart failure or known reduced LCEF &lt; 55%&#xD;
&#xD;
               8. INR ≥1.5 or other evidence of impaired hepatic function.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique -hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice BARLESI</last_name>
    <email>fabrise.barlesi@univ-amu.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>pascale TOMASINI</last_name>
    <phone>+33 (0)4 91 38 46 44</phone>
    <email>pascale.tomasini@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jean-olivier ARNAUD</last_name>
      <email>drci@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale TOMASINI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>February 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2019</study_first_posted>
  <last_update_submitted>September 21, 2022</last_update_submitted>
  <last_update_submitted_qc>September 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03833440
org study id: 2018-21
secondary id: 2018-000914-39
nct id: NCT03833440
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Research Hypothesis Lung cancer is the leading cause of cancer-related mortality in France
      and in western countries, accounting for more than 1.8 million new cases and 1.5 million
      deaths worldwide in 2012. Recent advances in the management of patients with Non-small Cell
      Lung Cancer Patients (NSCLC) include the use of therapies targeting oncogenes but a molecular
      alteration is currently found in only the half of the non-squamous NSCLC . More recently,
      immune check point inhibitors (ICI), firstly targeting PD-(L)1, became available and
      demonstrate an overall survival advantage over standard second-line chemotherapy both in
      squamous and non-squamous NSCLC. Unfortunately, this global overall survival benefit is
      driven by approximately 20% of the patient's population while a large majority of patients is
      in fact progressing in the first weeks of treatment.

      In the context of personalized medicine, innovative immunotherapy strategies in oncology are
      based on the principle of immune-contexture and require:

        -  The identification of biomarkers for assessing the specific immune-contexture of each
           patient (microenvironment, tumors and effector cells)

        -  The development of new treatments targeting their appropriate effector cells in
           monotherapy or combination treatments.

      The current PIONEER-Clinical study is aimed at assessing how to overcome resistance to ICIs
      monotherapies or ICI in combination with platinum-based chemotherapies, with experimental
      precision immunotherapies combined to Durvalumab in 2nd, 3rd or 4th line, in advanced NSCLC
      progressors patients after up to 18more than 6 w. of anti PD (L) 1. for ICIs monotherapies
      and after more than 12w. of anti PD(L)1 in combination with chemotherapies.

      Some supplementary blood and tissue samples are aimed at identification of personalized
      patients' biomarkers, correlation of them with the efficacy endpoints, in order to better
      understand mechanisms of resistance and improve their future treatment.
Study Design:

      During a mandatory post treatment 28-day wash-out period, 135 advanced NSCLC patients with
      progressive disease evaluated between 6 and 18w. of a second or third line ICI monotherapy;
      will undergo a screening visit. After signing an informed written consent, if they are found
      eligible, their participation in the study will ensue.

      Treatment allocation will be performed using the randomization module of the eCRF, :

        -  Arm A: combination of Durvalumab (MEDI4736) + Monalizumab (IPH2201), to target a PD-L1
           co-inhibitory pathway

        -  Arm B: combination of Durvalumab + oleclumab (MEDI9447), to target limitations of
           antitumor T-cell immunity caused by adenosine receptor signaling (inclusions closed on
           May 10, 2021)

        -  Arm C: combination of Durvalumab + AZD6738, to potentially enhance anti- tumour T-cell
           responses

        -  Arm D: a standard third or forth-line chemotherapy maintenance (Docetaxel)

        -  Arm E : combination of Durvalumab + MET kinase inhibitor Savolitinib (AZD6094)

      A maximum of 120 patients will be randomized, with 30 patients per arm (4 arms).
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Arm A: combination of Durvalumab + NKG2A inhibitor Monalizumab (IPH2201), to target a PD-L1 co-inhibitory pathway
Arm B: combination of Durvalumab + CD73 antibody MEDI9447, to target limitations of antitumor T-cell immunity caused by adenosine receptor signaling
Arm C: combination of Durvalumab + ATR inhibitor AZD6738, to potentially enhance anti- tumour T-cell responses
Arm D: a standard third or forth-line chemotherapy maintenance (Docetaxel).
Arm E : combination of Durvalumab + MET kinase inhibitor Savolitinib (AZD6094)
primary purpose: Treatment
masking: None (Open Label)
measure: the 12-week Disease Control Rate
time frame: 12 weeks
description: in each arm of treatment
measure: Overall Response Rate
time frame: 12 months
description: the proportion of patients with complete response (CR) or partial response (PR) as best overall response over the treatment period.
measure: Progression-free survival (PFS)
time frame: 12 months
measure: PFS Ratio
time frame: 12 months
description: the date of randomization until the date of event defined as the first documented progression or death from any cause.
measure: Overall Survival (OS)
time frame: 6 months
description: measured from the date of randomization to the date of death from any cause
measure: Duration of Response
time frame: 4years
description: measured in to patients whose Best overall response is either CR or PR. It will be measured from the time of first documented response (CR or PR) until the first documented disease progression or death due to underlying cancer.
arm group label: Durvalumab + Monalizumab
arm group type: Experimental
arm group label: Durvalumab + MEDI9447
arm group type: Experimental
arm group label: Durvalumab + AZD6738
arm group type: Experimental
arm group label: Docetaxel
arm group type: Active Comparator
arm group label: durvalumab+savolitinib
arm group type: Experimental
intervention type: Drug
intervention name: Durvalumab (MEDI4736)
description: 1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days
EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days
c=cycle D= day
arm group label: Durvalumab + AZD6738
arm group label: Durvalumab + MEDI9447
arm group label: Durvalumab + Monalizumab
arm group label: durvalumab+savolitinib
intervention type: Drug
intervention name: Monalizumab (IPH2201)
description: 1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days
c=cycle D= day
arm group label: Durvalumab + Monalizumab
intervention type: Drug
intervention name: Oleclumab (MEDI9447)
description: 3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.
c=cycle D= day
arm group label: Durvalumab + MEDI9447
intervention type: Drug
intervention name: Ceralasertib (AZD6738)
description: 240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.
CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days
c=cycle D= day
arm group label: Durvalumab + AZD6738
intervention type: Drug
intervention name: DOCETAXEL
description: 75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days
c=cycle D= day
arm group label: Docetaxel
intervention type: Drug
intervention name: Savolitinib
description: 600 mg QD
1 cycle = 28 days
arm group label: durvalumab+savolitinib
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: jean-olivier ARNAUD
role: Study Director
affiliation: Assistance Publique -hôpitaux de Marseille
last name: Fabrice BARLESI
email: fabrise.barlesi@univ-amu.fr
last name: pascale TOMASINI
phone: +33 (0)4 91 38 46 44
email: pascale.tomasini@ap-hm.fr
facility: 
status: Recruiting
contact: 
investigator: 
country: France
responsible party type: Sponsor
mesh term: Lung Neoplasms
mesh term: Carcinoma, Non-Small-Cell Lung
mesh term: Docetaxel
mesh term: Durvalumab